A European industrial group signs a letter of intent to acquire a controlling stake in a Chinese manufacturer. The commercial logic is sound. The price is agreed. Then the regulatory process begins – and what looked like a six-month deal stretches well past a year, with filings rejected for procedural deficiencies and two government bodies requesting supplementary documentation on the same transaction. The window to integrate the target narrows. Competitors move. The opportunity that justified the deal in the first place starts to erode.
Cross-border mergers involving China require sequential approval from multiple Chinese regulatory authorities, including the State Administration for Market Regulation (SAMR) for antitrust clearance and the relevant industry regulator for sector-specific consent. The precise pathway depends on whether the target is a domestic Chinese company, a listed entity, or a wholly foreign-owned enterprise (WFOE). Most transactions take between six and eighteen months from signing to closing, depending on sector sensitivity and deal structure.
This guide walks through the step-by-step regulatory process for cross-border M&A involving Chinese parties, identifies the documentary requirements at each stage. Flags the errors that most frequently delay or derail transactions. Additionally, provides a decision framework for choosing the right structure before the first filing is made.
Understanding China's regulatory architecture for cross-border M&A
No single authority governs cross-border mergers involving Chinese entities. Several regulators each hold a distinct veto, and their processes run partly in sequence and partly in parallel. Failing to understand how these authorities interact is the single most common cause of extended timelines.
The first layer is China's antitrust legislation, administered by SAMR. Where the combined revenues of the merging parties exceed the statutory thresholds, a pre-closing filing is mandatory. SAMR operates a formal review clock – typically thirty calendar days for a Phase I review, extendable to ninety days and, in complex cases, further extended with the parties' agreement. Deals that raise competition concerns in concentrated domestic markets can enter a full Phase II investigation lasting up to six months.
The second layer is foreign investment review. China's investment legislation establishes a Negative List (the schedule of restricted and prohibited sectors for foreign investors). Acquisitions in restricted sectors require additional approval, often from the relevant industry ministry. Prohibited sectors are closed to foreign ownership entirely, regardless of deal structure. Investors who identify a target without first checking its Negative List classification risk structuring an entire transaction around a regulatory pathway that does not exist.
The third layer is the State Administration of Foreign Exchange (SAFE) regime, which governs cross-border capital flows. When a foreign acquirer purchases equity in a Chinese company, the inbound purchase price must be registered with SAFE, and the target's foreign exchange account must be properly established before funds can flow. Delays at SAFE – frequently caused by documentation gaps in the share purchase agreement (SPA) – can hold up closing even after all substantive approvals are in hand.
For transactions involving listed Chinese companies, the China Securities Regulatory Commission (CSRC) adds a fourth layer. Acquisitions of significant stakes in A-share or H-share listed entities trigger mandatory disclosure and, in some cases, a mandatory offer obligation under securities legislation.
In the most sensitive sectors – defence, critical infrastructure, or areas the State Council designates as strategically important – a national security review process administered at the State Council level may apply. This review has no fixed statutory clock and can substantially extend the overall timeline.
For international businesses comparing regulatory regimes, our guide to cross-border mergers in the UAE provides a useful point of reference for understanding how a different high-growth jurisdiction structures its own foreign investment approval process.
Step-by-step timeline and documentary requirements
The regulatory process for a cross-border merger involving China broadly follows five stages. Each stage has distinct documentary requirements and, in many cases, Chinese-language submissions are mandatory regardless of whether the parties' transaction documents are in English.
Stage 1 – Pre-signing due diligence (four to eight weeks). Before a share purchase agreement is executed, the acquirer must conduct legal, financial, and regulatory due diligence on the target. In the Chinese context, due diligence carries particular weight because corporate legislation in China imposes specific disclosure obligations on sellers. Additionally. Representations and warranties in the SPA must be calibrated to what can actually be verified through Chinese public registries. Key items include: corporate registration status with the State Administration for Market Regulation, land use rights held by the target, any pending enforcement actions, and the target's compliance record under employment legislation and environmental legislation.
A common error at this stage is relying solely on documents provided by the seller. Public registries in China – including the national enterprise credit system – contain information that sellers sometimes omit from their disclosure schedules. Independently verifying the target's registered capital, shareholder structure, and any encumbrances on its assets before the SPA is signed avoids post-signing disputes over closing conditions.
Stage 2 – Signing and pre-filing structuring (two to four weeks). Once the SPA is executed, the parties must determine which filings are required and in what sequence. The SPA itself must include closing conditions that accurately reflect each regulatory approval needed. A poorly drafted conditions precedent clause – one that omits a required approval or misstates the approval standard – can prevent closing even where all substantive requirements have been satisfied.
At this stage, the parties also decide whether the transaction will be structured as a share acquisition or an asset acquisition. Share acquisitions of Chinese companies transfer all existing liabilities, including contingent tax liabilities under China's tax legislation. Asset acquisitions avoid this but require separate approvals for each transferred asset and are often more cumbersome where the target holds land use rights or operating licences.
Stage 3 – Regulatory filings (three to twelve months, depending on pathway). The SAMR antitrust filing, where required, is typically the first submission. The filing package includes a detailed description of the transaction, market share data for affected product and geographic markets, and a competitive effects analysis. SAMR may request supplementary information, which pauses the review clock. Parties should budget at least three months for a straightforward Phase I clearance and significantly more if the transaction involves markets where the combined entity holds a dominant or near-dominant position.
In parallel, the foreign investment filing is made through the Ministry of Commerce (MOFCOM) foreign investment management system. For sectors outside the Negative List, this is a record-filing rather than an approval, taking approximately ten to fifteen business days. For restricted sectors, the process converts into a substantive approval with a longer and less predictable timeline.
SAFE registration follows approval of the equity transfer. The acquirer's bank and the target's bank must both be engaged early, as SAFE documentation requirements vary by bank and errors in the account registration process are a frequent source of last-minute delay.
Stage 4 – Closing mechanics (two to four weeks after all approvals received). Closing in a Chinese cross-border transaction involves updating the target's corporate registration with the local market supervision bureau. Amending the business licence to reflect the new shareholder. Additionally, – where the target is a WFOE – updating the WFOE registration documents. The updated business licence is the operative document confirming the change of control. Until it is issued, the acquirer does not hold legal title to the equity even if all economic consideration has been paid.
For transactions where the target has employees, employment legislation in China requires that any change of control affecting employment terms be communicated to employees through the enterprise trade union or employee representative body. Failure to follow this process can trigger post-closing labour disputes.
Stage 5 – Post-closing integration and compliance (ongoing). Following closing, the acquirer must ensure the target's ongoing compliance with China's corporate legislation. This includes annual reporting obligations. Foreign exchange compliance under SAFE rules. Additionally, – where applicable – obligations under data protection legislation governing cross-border data transfers. Acquirers who treat closing as the end of the regulatory process consistently underestimate post-closing compliance costs.
For a detailed analysis of the corporate governance obligations that arise once a Chinese entity is acquired, see our overview of corporate law matters in China.
Errors that delay or derail cross-border M&A in China
Foreign buyers make a consistent set of errors when approaching Chinese cross-border transactions. Understanding these in advance avoids the most costly delays.
The first and most consequential error is sector classification. Investors sometimes identify a target, conduct commercial due diligence, and negotiate price before verifying whether the sector is restricted or prohibited under the current Negative List. The Negative List is updated periodically, and the classification of a given business activity can shift between one version and the next. Completing a deal on the assumption that the prior year's Negative List still applies – when the current version has tightened restrictions – can result in a transaction that cannot close at all.
The second error is underestimating the scope of due diligence required for representations and warranties in the SPA. Foreign buyers sometimes import an SPA template from another jurisdiction with representations and warranties calibrated to a common law disclosure standard. Chinese corporate and tax legislation impose distinct concepts of liability that do not map neatly onto these templates. Representations about the target's tax compliance, for instance, must account for the treatment of value-added tax obligations under Chinese tax legislation – an area where under-reporting is frequently discovered post-closing.
The third error concerns CIETAC and dispute resolution. The China International Economic and Trade Arbitration Commission (CIETAC) is the most commonly used arbitral body for disputes arising from China-related M&A transactions. Many foreign buyers default to choosing the arbitration rules of a non-Chinese institution. such as the ICC. without considering whether a Chinese court will recognise and enforce an award rendered under those rules against a Chinese party with assets in China. The enforceability of foreign arbitral awards in China depends on both the applicable treaty framework and how the arbitration clause is drafted. A poorly drafted clause can leave a buyer with a valid award it cannot enforce against assets held onshore.
The fourth error is treating the SAMR filing as the only approval needed. In a significant proportion of transactions, buyers focus entirely on antitrust clearance and treat other approvals as administrative formalities. SAFE registration failures and business licence update delays have caused deals to stall for months after SAMR clearance was received.
The fifth error is failing to engage Chinese-qualified legal counsel early enough. Foreign counsel can advise on the cross-border structuring and the SPA. However, filings with SAMR, MOFCOM. Additionally. SAFE must be prepared and submitted in Mandarin by counsel with Chinese qualification or by the parties' Chinese advisers. Gaps in coordination between foreign and local counsel are a persistent source of inconsistency between the English-language transaction documents and the Chinese-language regulatory submissions – inconsistencies that regulators use as grounds to request supplementary information.
To explore how our team structures M&A advisory across the full transaction lifecycle in China, visit our M&A services page for China.
For a preliminary review of your transaction structure and the regulatory pathway it involves in China, email us at info@ferrazwhitmore.com.
Decision framework: choosing the right structure for your scenario
Not every cross-border transaction involving China follows the same path. The right structure depends on the acquirer's objectives, the target's sector, and the acquirer's existing presence in China. The following framework helps identify which approach fits which scenario.
Scenario A – Foreign acquirer with no existing Chinese presence, target outside the Negative List. This is the most straightforward pathway. A share acquisition of the target proceeds through MOFCOM record-filing, SAMR filing if thresholds are met, and SAFE registration. The acquirer should budget six to nine months from signing to closing. If market entry speed is the primary objective, acquiring an existing entity is generally faster than establishing a new WFOE from scratch.
Scenario B – Foreign acquirer with an existing WFOE, seeking to acquire a domestic Chinese competitor. Where the acquirer already operates a WFOE in China, the transaction adds a layer of intra-group corporate complexity. The WFOE may itself be the acquiring vehicle, which changes the SAFE registration pathway. Antitrust thresholds are calculated on the combined basis of the entire group, not just the Chinese operations. Acquirers sometimes underestimate their own combined turnover when assessing whether the SAMR filing threshold is met – a filing omission that carries significant risk under Chinese antitrust legislation.
Scenario C – Acquisition of a Chinese target in a restricted sector. This scenario requires a substantive approval from the relevant industry regulator before the transaction can proceed. Timelines are significantly less predictable than in Scenarios A or B. The acquirer must demonstrate that the transaction meets the policy objectives applicable to the sector, which may require commitments on local employment, technology retention, or investment levels. Deal structuring at the pre-signing stage must account for the possibility that conditions will be imposed, potentially affecting the economics agreed between the parties.
Scenario D – Acquisition of a Chinese listed company. Where the target is listed on a Chinese stock exchange, securities legislation imposes mandatory disclosure obligations triggered at defined ownership thresholds. An acquirer crossing these thresholds must make a public announcement. If a controlling stake is being acquired, a mandatory offer obligation may arise for remaining minority shareholders. The CSRC review adds to an already multi-layered process. Acquirers should verify, before signing, whether the target's listing rules impose any additional consent requirements from the stock exchange itself.
Self-assessment checklist before initiating a cross-border merger in China:
- Confirm the target's sector classification against the current Negative List before structuring the deal.
- Verify whether the combined turnover of the parties triggers the SAMR antitrust filing threshold.
- Identify all regulatory approvals required and map their sequence before drafting closing conditions in the SPA.
- Confirm that your dispute resolution clause is enforceable against Chinese-based assets, whether under CIETAC rules or another mechanism.
- Engage Chinese-qualified legal counsel before the first regulatory submission is prepared.
To discuss a tailored strategy for your cross-border merger involving China, reach out to us at info@ferrazwhitmore.com.
Frequently asked questions
Q: How long does a cross-border merger involving a Chinese company typically take to close?
A: The total timeline depends on the regulatory pathway chosen and the sectors involved. For a straightforward transaction with no sensitive-sector exposure, a realistic minimum is six to nine months from signing to closing. Deals touching restricted sectors or requiring State Council review can take twelve to eighteen months or longer.
Q: Do foreign buyers always need SAMR antitrust clearance when acquiring a Chinese company?
A: Not automatically. The SAMR filing obligation is triggered only when the combined parties meet the turnover thresholds set out in China's antitrust legislation. Transactions below these thresholds do not require a mandatory pre-closing antitrust filing, though other approvals may still apply.
Q: Is it a misconception that a wholly foreign-owned enterprise structure is always the fastest entry route into China?
A: Yes. While a WFOE is well-established and avoids many joint-venture complications, establishing one from scratch typically takes three to five months in itself. A cross-border share acquisition of an existing Chinese entity can sometimes achieve market presence faster, provided the target is clean and the regulatory filings proceed without complications. Engaging a lawyer in China with cross-border M&A experience is essential to evaluating which route is faster for a given set of facts.
About Ferraz & Whitmore
Ferraz & Whitmore is an international law firm based in Lisbon, advising business clients across 46 jurisdictions. Our team combines Portuguese civil law expertise with English common law tradition to deliver cross-border legal solutions in M&A transactions involving China and the wider Asia-Pacific region. We work with international entrepreneurs, institutional investors, and in-house legal teams who require results-oriented counsel across multiple regulatory systems. Our M&A practice covers the full transaction lifecycle – from pre-signing due diligence and SPA negotiation through to regulatory filings and post-closing integration. As a law firm in China-focused cross-border work, our Asia-Pacific team has supported clients through SAMR antitrust proceedings, MOFCOM filings, and CIETAC arbitration. The firm's Lisbon base provides direct access to Portuguese and EU regulatory systems, while our common law expertise supports enforcement and arbitration strategies in English-speaking jurisdictions. To discuss your cross-border merger involving China, contact us at info@ferrazwhitmore.com.
Disclaimer: This publication is provided for informational purposes only and does not constitute legal advice. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Ferraz & Whitmore assumes no liability for actions taken or not taken based on the contents of this material. For advice regarding your particular situation, please contact info@ferrazwhitmore.com.